Novel action of 7-O-galloyl-D-sedoheptulose isolated from Corni Fructus as a hypertriglyceridaemic agent

Journal of Pharmacy and Pharmacology

Volumn 61, Issue 5, 2009, Pages 653-661

  Yokozawa, Takako ^a   Park, Chan Hum ^a   Noh, Jeong Sook ^a   Tanaka, Takashi ^b   Cho, Eun Ju ^c  

^a UNIVERSITY OF TOYAMA   (Japan)

^b NAGASAKI UNIVERSITY   (Japan)

^c Pusan National University   (South Korea)

Author keywords

7 O galloyl D sedoheptulose; Cholesterol; Corni Fructus; Fructose; Hypertriglyceridaemia

Indexed keywords

7 O GALLOYL DEXTRO SEDOHEPTULOSE; ALANINE AMINOTRANSFERASE; ANTILIPEMIC AGENT; ASPARTATE AMINOTRANSFERASE; CHOLESTEROL; FENOFIBRATE; FRUCTOSE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; 7 O GALLOYL D SEDOHEPTULOSE; 7-O-GALLOYL-D-SEDOHEPTULOSE; FATTY ACID; HEPTOSE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PLANT EXTRACT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORNUS; CORNUS OFFICINALIS; DRUG EFFICACY; DRUG ISOLATION; DRUG MECHANISM; FRUIT; GENE EXPRESSION; HYPERGLYCEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; LIVER FUNCTION; LIVER WEIGHT; MALE; NONHUMAN; RAT; RECEPTOR UPREGULATION; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT GAIN; ANIMAL; BLOOD; BLOOD PRESSURE; CHEMISTRY; DIET; DOSE RESPONSE; DRUG EFFECT; GLUCOSE BLOOD LEVEL; ISOLATION AND PURIFICATION; LIVER; METABOLISM; WISTAR RAT;

ANIMALS; ANTILIPEMIC AGENTS; BLOOD GLUCOSE; BLOOD PRESSURE; CHOLESTEROL; CORNUS; DIET; DOSE-RESPONSE RELATIONSHIP, DRUG; FATTY ACIDS, NONESTERIFIED; FRUCTOSE; HEPTOSES; HYPERTRIGLYCERIDEMIA; LIVER; MALE; PLANT EXTRACTS; PPAR ALPHA; RATS; RATS, WISTAR; TRIGLYCERIDES;

EID: 85047686382     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1211/jpp.61.05.0015     Document Type: Article

References (49)

1. Gotto AM Jr. Triglyceride as a risk factor for coronary artery disease. Am J Cardiol 1998; 82: 22-25Q.
2. Yoshiike N et al. The degree of obesity based on body mass index, and relation between the risk factors of diabetes, high blood pressure and hyperlipidemia. J Jpn Soc Study Obesity 2000; 6: 4-17.
3. Research Committee for Metabolic Syndrome Diagnostic Criteria. Definition of metabolic syndrome and its diagnostic criteria. J Intern Med 2005; 94: 188-203.
4. Gerrits PM, Tsalikian E. Diabetes and fructose metabolism. Am J Clin Nutr 1993; 58: 796-799S.
5. Smith SM. High fructose corn syrup replaces sugar in processed food. Environ Nutr 1998; 11: 7-8.
6. Elliott SS et al. Fructose, weight gain, and the insulin resistance syndrome. Am J Clin Nutr 2002; 76: 911-922.
7. Chang JS et al. Chemoprevention against hepatocellular carcinoma of Cornus officinalis in vitro. Am J Clin Med 2004; 32: 717-725.
8. Liou SS et al. Corni fructus as the major herb of Die-Huang-Wan for lowering plasma glucose in Wistar rats. J Pharm Pharmacol 2004; 56: 1443-1447.
9. Lee SO et al. Corni fructus scavenges hydroxyl radicals and decreases oxidative stress in endothelial cells. J Med Food 2006; 9: 594-598.
10. Kimura Y et al. Effects of Japanese and Chinese traditional medicine "Hachimi-Gan" ("Ba-Wei-Wan") on lipid metabolism in rats fed high sugar diet. Planta Med 1987; 53: 128-131.
11. Miyamoto K et al. Relationship between the structures and the antitumor activities of tannins. Chem Pharm Bull 1987; 35: 814-822.
12. Fukuchi K et al. Inhibition of herpes simplex virus infection by tannins and related compounds. Antiviral Res 1989; 11: 285-297.
13. Okuda T et al. Ellagitannins as active constituents of medicinal plants. Planta Med 1989; 55: 117-122.
14. Okuda T et al. Pharmacologically active tannins isolated from medicinal plants. Basic Life Sci 1992; 59: 539-569.
15. Xu HQ, Hao HP. Effects of iridoid total glycoside from Cornus officinalis on prevention of glomerular overexpression of transforming growth factor beta 1 and matrixes in an experimental diabetes model. Biol Pharm Bull 2004; 27: 1014-1018.
16. Yamabe N et al. Beneficial effect of Corni Fructus, a constituent of Hachimi-jio-gan, on advanced glycation endproduct-mediated renal injury in streptozotocin-treated diabetic rats. Biol Pharm Bull 2007; 30: 520-526.
17. Yamabe N et al. Identification of antidiabetic effect of iridoid glycosides and low molecular weight polyphenol fractions of Corni Fructus, a constituent of Hachimi-jio-gan, in streptozotocininduced diabetic rats. Biol Pharm Bull 2007; 30: 1289-1296.
18. Xie Y, Zhao Y. Synthesis of 7-O-galloyl-D-sedoheptulose. Carbohydr Res 2007; 342: 1510-1513.
19. Zhang Y et al. A sedoheptulose gallate from the fruits of Cornus officinalis. Acta Pharm Sin 1999; 34: 153-155.
20. Lee SH et al. Sedoheptulose digallate from Cornus officinalis. Phytochemistry 1989; 28: 3469-3472.
21. Folch J et al. A simple method for the isolation and purification of total lipids from animal tissues. J Biol Chem 1957; 226: 497-509.
22. Sakurai H et al. Activation of transcription factor NF-κB in experimental glomerulonephritis in rats. Biochim Biophys Acta 1996; 1316: 132-138.
23. Sleder J et al. Hyperinsulinemia in fructose-induced hypertriglyceridemia in the rat. Metabolism 1980; 29: 303-305.
24. Bezerra RMN et al. A high fructose diet affects the early steps of insulin action in muscle and liver of rats. J Nutr 2000; 130: 1531-1535.
25. Tziomalos K, Athyros VG. Fenofibrate: a novel formulation (Triglice™) in the treatment of lipid disorders: a review. Int J Nanomedicine 2006; 1: 129-147.
26. Barter PJ, Rye KA. Is there a role for fibrates in the management of dyslipidemia in the metabolic syndrome? Arterioscler Thromb Vasc Biol 2008; 28: 39-46.
27. Levi B, Werman MJ. Long-term fructose consumption accelerates glycation and several age-related variables in male rats. J Nutr 1998; 128: 1442-1449.
28. Catena C et al. Cellular mechanisms of insulin resistance in rats with fructose-induced hypertension. Am J Hypertens 2003; 16: 973-978.
29. Kelley GL et al. High dietary fructose induces a hepatic stress response resulting in cholesterol and lipid dysregulation. Endocrinology 2004; 145: 548-555.
30. Basciano H et al. Fructose, insulin resistance, and metabolic dyslipidemia. Nutr Metab 2005; 2: 5-18.
31. Mayes PA. Intermediary metabolism of fructose. Am J Clin Nutr 1993; 58: 754-765S.
32. Fried SK, Rao SP. Sugars, hypertriglyceridemia, and cardiovascular disease. Am J Clin Nutr 2003; 78: 873-880S.
33. Lakka HM et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002; 288: 2709-2716.
34. Park J et al. Chronic exogenous insulin and chronic carbohydrate supplementation increase de novo VLDL triglyceride fatty acid production in rats. J Lipid Res 1997; 38: 2529-2536.
35. Horton JD et al. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest 2002; 109: 1125-1131.
36. Horton JD et al. Activation of cholesterol synthesis in preference to fatty acid synthesis in liver and adipose tissue of transgenic mice overproducing sterol regulatory elementbinding protein-2. J Clin Invest 1998; 101: 2331-2339.
37. Aoyama T et al. Altered constitutive expression of fatty acid-metabolizing enzymes in mice lacking the peroxisome proliferator-activated receptor α (PPARα). J Biol Chem 1998; 273: 5678-5684.
38. Leone TC et al. A critical role for the peroxisome proliferatoractivated receptor α (PPARα) in the cellular fasting response: the PPARα-null mouse as a model of fatty acid oxidation disorders. Proc Natl Acad Sci USA 1999; 96: 7473-7478.
39. Desvergne B, Wahli W. Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr Rev 1999; 20: 649-688.
40. Lefebvre P et al. Sorting out the roles of PPARα in energy metabolism and vascular homeostasis. J Clin Invest 2006; 116: 571-580.
41. The FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005; 366: 1849-1861.
42. Nagai Y et al. Amelioration of high fructose-induced metabolic derangements by activation of PPARα. Am J Physiol - Endocrinol Metab 2002; 282: E1180-1190.
43. Bensinger SJ, Tontonoz P. Integration of metabolism and inflammation by lipid-activated nuclear receptors. Nature 2008; 454: 470-477.
44. Delerive P et al. Peroxisome proliferator-activated receptor a negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-κB and AP-1. J Biol Chem 1999; 274: 32048-32054.
45. Chung SW et al. Oxidized low density lipoprotein inhibits interleukin-12 production in lipopolysaccharide-activated mouse macrophages via direct interactions between peroxisome proliferator-activated receptor-γ and nuclear factor-κB. J Biol Chem 2000; 275: 32681-32687.
46. Syrovets T et al. Ciglitazone inhibits plasmin-induced proinflammatory monocyte activation via modulation of p38 MAP kinase activity. Thromb Haemost 2002; 88: 274-281.
47. Peters JM et al. Peroxisome proliferator-activated receptor-a and liver cancer: where do we stand? J Mol Med 2005; 83: 774-785.
48. Hayakawa T et al. Studies on the risk factors for fenofibrateinduced elevation of liver function tests. Yakugaku Zasshi 2002; 122: 169-175.
49. Dohmen K et al. Fenofibrate-induced liver injury. World J Gastroenterol 2005; 11: 7702-7703.